{"filing":{"accession_number":"0001628280-26-066969","cik":"0001704292","ticker":"ZLAB","company_name":"Zai Lab Ltd","form":"8-K","filing_date":"2026-10-23","report_date":"2026-10-22","primary_document":"zlab-20261022.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1704292/000162828026066969/zlab-20261022.htm"},"events":[{"id":37396,"run_id":34472,"accession_number":"0001628280-26-066969","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Zai Lab entered into a Securities Purchase Agreement on October 22, 2026, to sell 11,340,000 ADSs at $22.04 per ADS in a private placement generating approximately $250 million in gross proceeds. The company also entered into a Registration Rights Agreement requiring registration of the resold securities within 15 days of closing. This unregistered equity issuance to accredited investors is a classic PIPE transaction material to investors assessing ownership dilution and capital structure.","company_name":"Zai Lab Ltd","ticker":"ZLAB","filing_date":"2026-10-23","form":"8-K","submitted_at":null,"items":[{"id":42094,"accession_number":"0001628280-26-066969","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Zai Lab entered into a Securities Purchase Agreement on October 22, 2026, to sell 11,340,000 ADSs at $22.04 per ADS in a private placement, generating approximately $250 million in gross proceeds. This is a classic PIPE (private investment in public equity) transaction—an unregistered sale of equity securities to accredited investors. The company also entered into a Registration Rights Agreement requiring registration of the resold securities within 15 days of closing. Such dilutive equity issuances are material to investors as they affect ownership dilution and capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-23T10:07:58.665725+00:00","company_name":"","ticker":null,"filing_date":""},{"id":42095,"accession_number":"0001628280-26-066969","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Item 3.02 explicitly discloses an unregistered sale of equity securities under a Securities Purchase Agreement referenced in Item 1.01. The filing states \"The securities described above under Item 1.01 have not been registered under the Securities Act of 1933\" and that the company is relying on Section 4(a)(2) and Regulation D exemptions, with restrictive legends to be affixed. This is a classic private placement of equity securities, which is a dilutive issuance material to investors assessing capital structure and ownership dilution.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-23T10:07:58.665725+00:00","company_name":"","ticker":null,"filing_date":""},{"id":42097,"accession_number":"0001628280-26-066969","item_number":"8.01","item_title":"Other Events.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"The Item 8.01 disclosure references a \"Private Placement\" announced via press release on October 22, 2026 (Exhibit 99.2). While the full press release text is not provided in the materials shown, the reference to a private placement in an 8-K Item 8.01 context, combined with the corporate presentation deck discussing the company's pipeline and strategic positioning, indicates an unregistered equity issuance. Private placements are a common form of dilutive capital raising at biotech companies and typically require 8-K disclosure under Item 3.02 or Item 8.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-23T10:07:58.665725+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":37397,"run_id":34472,"accession_number":"0001628280-26-066969","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Zai Lab published an updated corporate presentation on October 23, 2026, disclosing clinical trial data and development updates for its lead oncology program (Zoci/zocilurtatug pelitecan), including ESMO 2026 data showing an 81.8% ORR with the doublet regimen in first-line SCLC and a favorable tolerability profile. This material clinical milestone disclosure affects investor assessment of the company's drug development trajectory and commercial prospects.","company_name":"Zai Lab Ltd","ticker":"ZLAB","filing_date":"2026-10-23","form":"8-K","submitted_at":null,"items":[{"id":42096,"accession_number":"0001628280-26-066969","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The filing discloses an updated corporate presentation published on October 23, 2026, containing clinical trial data and development updates for Zai Lab's lead oncology program (Zoci/zocilurtatug pelitecan). The presentation highlights ESMO 2026 clinical data showing efficacy and safety results in first-line SCLC, including an 81.8% ORR with the doublet regimen and favorable tolerability profile. This represents a material operational/clinical milestone disclosure—the presentation of significant clinical trial results and pipeline progress—that would affect a reasonable investor's assessment of the company's drug development trajectory and commercial prospects, though it is not a formal earnings release or a specific named event type.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-23T10:07:58.665725+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":42094,"accession_number":"0001628280-26-066969","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Zai Lab entered into a Securities Purchase Agreement on October 22, 2026, to sell 11,340,000 ADSs at $22.04 per ADS in a private placement, generating approximately $250 million in gross proceeds. This is a classic PIPE (private investment in public equity) transaction—an unregistered sale of equity securities to accredited investors. The company also entered into a Registration Rights Agreement requiring registration of the resold securities within 15 days of closing. Such dilutive equity issuances are material to investors as they affect ownership dilution and capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-23T10:07:58.665725+00:00","company_name":"Zai Lab Ltd","ticker":"ZLAB","filing_date":"2026-10-23"},{"id":42095,"accession_number":"0001628280-26-066969","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Item 3.02 explicitly discloses an unregistered sale of equity securities under a Securities Purchase Agreement referenced in Item 1.01. The filing states \"The securities described above under Item 1.01 have not been registered under the Securities Act of 1933\" and that the company is relying on Section 4(a)(2) and Regulation D exemptions, with restrictive legends to be affixed. This is a classic private placement of equity securities, which is a dilutive issuance material to investors assessing capital structure and ownership dilution.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-23T10:07:58.665725+00:00","company_name":"Zai Lab Ltd","ticker":"ZLAB","filing_date":"2026-10-23"},{"id":42096,"accession_number":"0001628280-26-066969","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The filing discloses an updated corporate presentation published on October 23, 2026, containing clinical trial data and development updates for Zai Lab's lead oncology program (Zoci/zocilurtatug pelitecan). The presentation highlights ESMO 2026 clinical data showing efficacy and safety results in first-line SCLC, including an 81.8% ORR with the doublet regimen and favorable tolerability profile. This represents a material operational/clinical milestone disclosure—the presentation of significant clinical trial results and pipeline progress—that would affect a reasonable investor's assessment of the company's drug development trajectory and commercial prospects, though it is not a formal earnings release or a specific named event type.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-23T10:07:58.665725+00:00","company_name":"Zai Lab Ltd","ticker":"ZLAB","filing_date":"2026-10-23"},{"id":42097,"accession_number":"0001628280-26-066969","item_number":"8.01","item_title":"Other Events.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"The Item 8.01 disclosure references a \"Private Placement\" announced via press release on October 22, 2026 (Exhibit 99.2). While the full press release text is not provided in the materials shown, the reference to a private placement in an 8-K Item 8.01 context, combined with the corporate presentation deck discussing the company's pipeline and strategic positioning, indicates an unregistered equity issuance. Private placements are a common form of dilutive capital raising at biotech companies and typically require 8-K disclosure under Item 3.02 or Item 8.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-23T10:07:58.665725+00:00","company_name":"Zai Lab Ltd","ticker":"ZLAB","filing_date":"2026-10-23"}]}